BRAF mutations are frequently detectable in melanoma (50-60% of cases), papillary thyroid cancer (40-60%), colorectal cancer (about 5-10%), pilocytic astrocytoma (10-15%) and non-small-cell lung cancer (NSCLC; 3-5%). Here, BRAF is linked to melanoma.